Right ventricular adaptation and failure in pulmonary arterial hypertension

Canadian Journal of Cardiology

Volumn 31, Issue 4, 2015, Pages 391-406

  Ryan, John J ^a   Huston, Jessica ^a   Kutty, Shelby ^b   Hatton, Nathan D ^a   Bowman, Lindsay ^c   Tian, Lian ^c   Herr, Julia E ^c   Johri, Amer M ^c   Archer, Stephen L ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ANGIOGENESIS; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; DESENSITIZATION; DOWN REGULATION; DYSPNEA; FOOT EDEMA; FUNCTIONAL STATUS; HEART AFTERLOAD; HEART ATRIUM ENLARGEMENT; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART HYPERTROPHY; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART PERFORMANCE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOKINESIA; LUNG BLOOD VESSEL; LUNG CIRCULATION; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL RESPIRATION; MORPHOLOGICAL ADAPTATION; MYOCARDIAL HIBERNATION; NONHUMAN; PULMONARY HYPERTENSION; RECEPTOR DOWN REGULATION; RELAXATION TIME; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX RADIOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; ADAPTATION; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE COURSE; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTENSION, PULMONARY; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84961288123     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.01.023     Document Type: Review

References (131)

1. Hoeper M.M., Bogaard H.J., Condliffe R., et al. Definitions and diagnosis of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D42-50.
2. Ryan J.J., Archer S.L. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 2014, 115:176-188.
3. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association. Circulation 2009, 119:2250-2294.
4. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
5. Campo A., Mathai S.C., Le Pavec J., et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 2011, 38:359-367.
6. Ryan J.J., Butrous G., Maron B.A. The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts. Pulm Circ 2014, 4:441-445.
7. Clinicaltrials.gov. The Use of Impella RP Support System in Patients With Right Heart Failure. Available at: Accessed January 14, 2015. http://clinicaltrials.gov/show/NCT01777607.
8. Mehra M.R., Park M.H., Landzberg M.J., et al. Right heart failure: toward a common language. JHeart Lung Transplant 2014, 33:123-126.
9. Voelkel N.F., Quaife R.A., Leinwand L.A., et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006, 114:1883-1891.
10. Naeije R., Vachiery J.L., Yerly P., Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013, 41:217-223.
11. Bogaard H.J., Abe K., Vonk Noordegraaf A., Voelkel N.F. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009, 135:794-804.
12. Piao L., Fang Y.H., Parikh K., et al. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. JMol Med 2013, 91:1185-1197.
13. Rich S., Pogoriler J., Husain A.N., et al. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010, 138:1234-1239.
14. Piao L., Fang Y.H., Parikh K.S., et al. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 2012, 126:2859-2869.
15. van de Veerdonk M.C., Kind T., Marcus J.T., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. JAm Coll Cardiol 2011, 58:2511-2519.
16. Vonk-Noordegraaf A., Haddad F., Chin K.M., et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. JAm Coll Cardiol 2013, 62:D22-33.
17. Benza R.L., Miller D.P., Gomberg-Maitland M., et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010, 122:164-172.
18. Tongers J., Schwerdtfeger B., Klein G., et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007, 153:127-132.
19. Matthews J.C., McLaughlin V. Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management. Curr Cardiol Rev 2008, 4:49-59.
20. Rubin L.J., Badesch D.B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005, 143:282-292.
21. Rivero Carvallo J.M. Carvallo sign of tricuspid insufficiency. Archivos del Instituto de cardiologia de Mexico 1946, 16:531. [in Spanish].
22. Steel G. The murmur of high-pressure in the pulmonary artery. Med Chron 1888, 9:182.
23. Cook D.J., Simel D.L. The rational clinical examination. Does this patient have abnormal central venous pressure?. JAMA 1996, 275:630-634.
24. Sanz J., Conroy J., Narula J. Imaging of the right ventricle. Cardiol Clin 2012, 30:189-203.
25. Addetia K., Bhave N.M., Tabit C.E., et al. Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points. Circ Cardiovasc Imaging 2014, 7:115-124.
26. Forfia P.R., Fisher M.R., Mathai S.C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006, 174:1034-1041.
27. Yeo T.C., Dujardin K.S., Tei C., et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998, 81:1157-1161.
28. Champion H.C., Michelakis E.D., Hassoun P.M. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009, 120:992-1007.
29. Haeck M.L., Scherptong R.W., Marsan N.A., et al. Prognostic value of right ventricular longitudinal peak systolic strain in patients with pulmonary hypertension. Circ Cardiovasc Imaging 2012, 5:628-636.
30. Rudski L.G., Lai W.W., Afilalo J., et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. JAm Soc Echocardiogr 2010, 23:685-713. [quiz 786-688].
31. Ghio S., Klersy C., Magrini G., et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2010, 140:272-278.
32. Simon M.A., Pinsky M.R. Right ventricular dysfunction and failure in chronic pressure overload. Cardiol Res Pract 2011, 2011:568095.
33. Fukuda Y., Tanaka H., Sugiyama D., et al. Utility of right ventricular free wall speckle-tracking strain for evaluation of right ventricular performance in patients with pulmonary hypertension. JAm Soc Echocardiogr 2011, 24:1101-1108.
34. Meris A., Faletra F., Conca C., et al. Timing and magnitude of regional right ventricular function: a speckle tracking-derived strain study of normal subjects and patients with right ventricular dysfunction. JAm Soc Echocardiogr 2010, 23:823-831.
35. Sachdev A., Villarraga H.R., Frantz R.P., et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. Chest 2011, 139:1299-1309.
36. Pirat B., McCulloch M.L., Zoghbi W.A. Evaluation of global and regional right ventricular systolic function in patients with pulmonary hypertension using a novel speckle tracking method. Am J Cardiol 2006, 98:699-704.
37. Benza R., Biederman R., Murali S., Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. JAm Coll Cardiol 2008, 52:1683-1692.
38. Grothues F., Moon J.C., Bellenger N.G., et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004, 147:218-223.
39. van Wolferen S.A., Marcus J.T., Boonstra A., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007, 28:1250-1257.
40. Swift A.J., Rajaram S., Campbell M.J., et al. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2014, 7:100-106.
41. Freed B.H., Gomberg-Maitland M., Chandra S., et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. JCardiovasc Magn Reson 2012, 14:11.
42. Katz J., Whang J., Boxt L.M., Barst R.J. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. JAm Coll Cardiol 1993, 21:1475-1481.
43. Frank H., Globits S., Glogar D., Neuhold A., Kneussl M., Mlczoch J. Detection and quantification of pulmonary artery hypertension with MR imaging: results in 23 patients. AJR Am J Roentgenol 1993, 161:27-31.
44. Dellegrottaglie S., Sanz J., Poon M., et al. Pulmonary hypertension: accuracy of detection with left ventricular septal-to-free wall curvature ratio measured at cardiac MR. Radiology 2007, 243:63-69.
45. Vonk-Noordegraaf A., Marcus J.T., Gan C.T., Boonstra A., Postmus P.E. Interventricular mechanical asynchrony due to right ventricular pressure overload in pulmonary hypertension plays an important role in impaired left ventricular filling. Chest 2005, 128:628S-630S.
46. Ramani G.V., Gurm G., Dilsizian V., Park M.H. Noninvasive assessment of right ventricular function: will there be resurgence in radionuclide imaging techniques?. Curr Cardiol Rep 2010, 12:162-169.
47. Michelakis E.D., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003, 108:2066-2069.
48. Mauritz G.J., Kind T., Marcus J.T., et al. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest 2012, 141:935-943.
49. Marrone G., Mamone G., Luca A., et al. The role of 1.5T cardiac MRI in the diagnosis, prognosis and management of pulmonary arterial hypertension. Int J Cardiovasc Imaging 2010, 26:665-681.
50. van Wolferen S.A., van de Veerdonk M.C., Mauritz G.J., et al. Clinically significant change in stroke volume in pulmonary hypertension. Chest 2011, 139:1003-1009.
51. Gaine S. Pulmonary hypertension. JAMA 2000, 284:3160-3168.
52. Bilchick K.C., Wise R.A. Paradoxical physical findings described by Kussmaul: pulsus paradoxus and Kussmaul's sign. Lancet 2002, 359:1940-1942.
53. Meyer T.E., Sareli P., Marcus R.H., et al. Mechanism underlying Kussmaul's sign in chronic constrictive pericarditis. Am J Cardiol 1989, 64:1069-1072.
54. Nadir A.M., Beadle R., Lim H.S. Kussmaul physiology in patients with heart failure. Circ Heart Fail 2014, 7:440-447.
55. Ryan J.J., Rich J.D., Thiruvoipati T., et al. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 2012, 163:589-594.
56. Kovacs G., Avian A., Pienn M., Naeije R., Olschewski H. Reading pulmonary vascular pressure tracings. How to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med 2014, 190:252-257.
57. Tedford R.J., Hassoun P.M., Mathai S.C., et al. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 2012, 125:289-297.
58. Sakamaki F., Satoh T., Nagaya N., et al. Correlation between severity of pulmonary arterial hypertension and 123I-metaiodobenzylguanidine left ventricular imaging. JNucl Med 2000, 41:1127-1133.
59. Carrio I. Cardiac neurotransmission imaging. JNucl Med 2001, 42:1062-1076.
60. Oikawa M., Kagaya Y., Otani H., et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. JAm Coll Cardiol 2005, 45:1849-1855.
61. Marsboom G., Wietholt C., Haney C.R., et al. Lung (18)F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 185:670-679.
62. Hagan G., Southwood M., Treacy C., et al. (18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: a proof-of-principle study. Pulm Circ 2011, 1:448-455.
63. Gomez A., Bialostozky D., Zajarias A., et al. Right ventricular ischemia in patients with primary pulmonary hypertension. JAm Coll Cardiol 2001, 38:1137-1142.
64. Vogel-Claussen J., Skrok J., Shehata M.L., et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology 2011, 258:119-127.
65. Bian X., Fu M., Mallet R.T., Bunger R., Downey H.F. Myocardial oxygen consumption modulates adenosine formation by canine right ventricle in absence of hypoxia. JMol Cell Cardiol 2000, 32:345-354.
66. Voelkel N.F., Gomez-Arroyo J., Abbate A., Bogaard H.J. Mechanisms of right heart failure-a work in progress and a plea for failure prevention. Pulm Circ 2013, 3:137-143.
67. Piao L., Sidhu V.K., Fang Y.H., et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. JMol Med (Berl) 2013, 91:333-346.
68. Ohira H., Beanlands R.S., Davies R.A., Mielniczuk L. The role of nuclear imaging in pulmonary hypertension. JNucl Cardiol 2015, 22:141-157.
69. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
70. Bristow M.R., Minobe W., Rasmussen R., et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. JClin Invest 1992, 89:803-815.
71. Ujeyl A., Inada K., Hillmann K., et al. Right heart function prediction of outcome in heart failure patients after catheter ablation for recurrent ventricular tachycardia. JACC Heart Fail 2013, 1:281-289.
72. Doesch C., Dierks D.M., Haghi D., et al. Right ventricular dysfunction, late gadolinium enhancement, and female gender predict poor outcome in patients with dilated cardiomyopathy. Int J Cardiol 2014, 177:429-435.
73. Grigioni F., Potena L., Galie N., et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. JHeart Lung Transplant 2006, 25:1241-1246.
74. Puwanant S., Priester T.C., Mookadam F., et al. Right ventricular function in patients with preserved and reduced ejection fraction heart failure. Eur J Echocardiogr 2009, 10:733-737.
75. Mohammed S.F., Hussain I., Abou Ezzeddine O.F., et al. Right ventricular function in heart failure with preserved ejection fraction: a community based study. Circulation 2014, 130:2310-2320.
76. Oosterhof T., Tulevski I.I., Vliegen H.W., Spijkerboer A.M., Mulder B.J. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am J Cardiol 2006, 97:1051-1055.
77. Haddad F., Doyle R., Murphy D.J., Hunt S.A. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008, 117:1717-1731.
78. Hopkins W.E., Waggoner A.D. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002, 89:34-38.
79. Kawut S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., Kimmel S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344-350.
80. Kuhn K.P., Byrne D.W., Arbogast P.G., et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003, 167:580-586.
81. Hopkins W.E., Ochoa L.L., Richardson G.W., Trulock E.P. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. JHeart Lung Transplant 1996, 15:100-105.
82. Fang Y.H., Piao L., Hong Z., et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. JMol Med (Berl) 2012, 90:31-43.
83. Cavasin M.A., Demos-Davies K., Horn T.R., et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res 2012, 110:739-748.
84. Zhao L., Chen C.N., Hajji N., et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012, 126:455-467.
85. Bogaard H.J., Mizuno S., Hussaini A.A., et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011, 183:1402-1410.
86. Piao L., Fang Y.H., Cadete V.J., et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. JMol Med (Berl) 2010, 88:47-60.
87. Guarracino F., Cariello C., Danella A., et al. Right ventricular failure: physiology and assessment. Minerva Anestesiol 2005, 71:307-312.
88. Archer S.L., Fang Y.H., Ryan J.J., Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ 2013, 3:144-152.
89. Bogaard H.J., Natarajan R., Henderson S.C., et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009, 120:1951-1960.
90. van Wolferen S.A., Marcus J.T., Westerhof N., et al. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 2008, 29:120-127.
91. Vlahakes G.J., Baer R.W., Uhlig P.N., et al. Adrenergic influence in the coronary circulation of conscious dogs during maximal vasodilation with adenosine. Circ Res 1982, 51:371-384.
92. Bian X., Williams A.G., Gwirtz P.A., Downey H.F. Right coronary autoregulation in conscious, chronically instrumented dogs. Am J Physiol 1998, 275:H169-H175.
93. Marsboom G., Toth P.T., Ryan J.J., et al. Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res 2012, 110:1484-1497.
94. Lundgrin E.L., Park M.M., Sharp J., et al. Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc 2013, 10:1-9.
95. McMurtry M.S., Bonnet S., Wu X., et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004, 95:830-840.
96. Michelakis E.D., McMurtry M.S., Wu X.C., et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002, 105:244-250.
97. Clinicaltrials.gov. Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension. Available at: Accessed January14, 2015. http://clinicaltrials.gov/ct2/show/NCT01083524.
98. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
99. Clinicaltrials.gov. Ranolazine and Pulmonary Hypertension. Available at: Accessed November 1,2014. http://www.clinicaltrials.gov/ct2/show/NCT01174173.
100. Dang C.V. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?. Cell Cycle 2010, 9:3884-3886.
101. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433.
102. Nootens M., Kaufmann E., Rector T., et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. JAm Coll Cardiol 1995, 26:1581-1585.
103. Brown L., Miller J., Dagger A., Sernia C. Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. JCardiovasc Pharmacol 1998, 31:108-115.
104. Usui S., Yao A., Hatano M., et al. Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. Circ J 2006, 70:1208-1215.
105. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. Adose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. NEngl J Med 1998, 339:1810-1816.
106. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138:78-86.
107. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. NEngl J Med 1991, 325:1468-1475.
108. Chatterjee S., Udell J.A., Sardar P., Lichstein E., Ryan J.J. Comparable benefit of beta-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. Can J Cardiol 2014, 30:898-903.
109. Tual L., Morel O.E., Favret F., et al. Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia. Pflugers Arch 2006, 452:371-379.
110. Grinnan D., Bogaard H.J., Grizzard J., et al. Treatment of group I pulmonary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med 2014, 189:1562-1564.
111. Clinicaltrials.gov. Carvedilol PAH A Pilot Study of Efficacy and Safety. Available at: Accessed January14, 2015. http://clinicaltrials.gov/show/NCT02120339.
112. Clinicaltrials.gov. PAHTCH (Carvedilol). Available at: Accessed January14, 2015. http://clinicaltrials.gov/ct2/show/NCT01586156.
113. Gupta V., Tonelli A.R., Krasuski R.A. Congenital heart disease and pulmonary hypertension. Heart Fail Clin 2012, 8:427-445.
114. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D34-41.
115. Marelli A.J., Mackie A.S., Ionescu-Ittu R., Rahme E., Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007, 115:163-172.
116. Engelfriet P.M., Duffels M.G., Moller T., et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007, 93:682-687.
117. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. JAm Coll Cardiol 2001, 37:183-188.
118. Lowe B.S., Therrien J., Ionescu-Ittu R., et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. JAm Coll Cardiol 2011, 58:538-546.
119. Duffels M.G., Engelfriet P.M., Berger R.M., et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007, 120:198-204.
120. Reddy S., Osorio J.C., Duque A.M., et al. Failure of right ventricular adaptation in children with tetralogy of Fallot. Circulation 2006, 114:I37-42.
121. Kaufman B.D., Desai M., Reddy S., et al. Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. JCardiac Fail 2008, 14:760-767.
122. Reddy S., Zhao M., Hu D.Q., et al. Physiologic and molecular characterization of a murine model of right ventricular volume overload. Am J Physiol Heart Circ Physiol 2013, 304:H1314-H1327.
123. Friedberg M.K., Cho M.Y., Li J., et al. Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-beta1 signaling and is abrogated by angiotensin receptor blockade. Am J Respir Cell Mol Biol 2013, 49:1019-1028.
124. Reddy S., Zhao M., Hu D.Q., et al. Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics 2012, 44:562-575.
125. Paulin R., Sutendra G., Gurtu V., et al. AmiR-208-Mef2 axis drives the de-compensation of right ventricular function in pulmonary hypertension. Circ Res 2015, 116:56-69.
126. Pullamsetti S.S., Doebele C., Fischer A., et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012, 185:409-419.
127. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
128. Sarkar J., Gou D., Turaka P., et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 2010, 299:L861-L871.
129. Wang G.Y., Yeh C.C., Jensen B.C., et al. Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol 2010, 298:H913-H920.
130. Rajagopalan V., Zhao M., Reddy S., et al. Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure. Am J Physiol Heart Circ Physiol 2013, 305:H551-H562.
131. Kitahori K., He H., Kawata M., et al. Development of left ventricular diastolic dysfunction with preservation of ejection fraction during progression of infant right ventricular hypertrophy. Circ Heart Fail 2009, 2:599-607.